Brokerages Set Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Target Price at $17.75

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has been given a consensus rating of “Moderate Buy” by the seven research firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $17.75.

A number of analysts have recently weighed in on ATRA shares. HC Wainwright reaffirmed a “neutral” rating on shares of Atara Biotherapeutics in a research report on Tuesday, January 28th. TD Cowen raised shares of Atara Biotherapeutics to a “strong-buy” rating in a research report on Friday, November 29th. RODMAN&RENSHAW cut shares of Atara Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 21st. Rodman & Renshaw assumed coverage on shares of Atara Biotherapeutics in a research report on Friday, December 20th. They issued a “buy” rating and a $25.00 price target on the stock. Finally, Canaccord Genuity Group reduced their price target on shares of Atara Biotherapeutics from $21.00 to $17.00 and set a “buy” rating on the stock in a research note on Friday, January 17th.

Institutional Investors Weigh In On Atara Biotherapeutics

A number of hedge funds have recently modified their holdings of ATRA. Geode Capital Management LLC lifted its position in Atara Biotherapeutics by 9.5% during the third quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock worth $380,000 after buying an additional 4,043 shares in the last quarter. State Street Corp grew its stake in shares of Atara Biotherapeutics by 52.3% in the 3rd quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock valued at $182,000 after buying an additional 7,680 shares during the period. FMR LLC increased its holdings in shares of Atara Biotherapeutics by 41.7% during the 3rd quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock worth $204,000 after buying an additional 7,381 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in Atara Biotherapeutics in the second quarter valued at approximately $79,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in Atara Biotherapeutics in the second quarter valued at $53,000. 70.90% of the stock is currently owned by institutional investors and hedge funds.

Atara Biotherapeutics Trading Down 4.1 %

Atara Biotherapeutics stock opened at $8.52 on Friday. Atara Biotherapeutics has a 1-year low of $5.40 and a 1-year high of $31.75. The firm has a market capitalization of $49.08 million, a price-to-earnings ratio of -0.33 and a beta of 0.46. The firm has a 50 day simple moving average of $11.62 and a 200 day simple moving average of $9.86.

Atara Biotherapeutics (NASDAQ:ATRA) last released its earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) EPS for the quarter, beating the consensus estimate of ($3.77) by $0.84. The business had revenue of $40.19 million for the quarter, compared to the consensus estimate of $23.00 million. During the same period in the prior year, the business posted ($16.50) EPS. On average, equities research analysts forecast that Atara Biotherapeutics will post -10.39 EPS for the current year.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.